Welcome to the POTP board, the DPP-IV company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Welcome to the POTP board, the DPP-IV company

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (52)	11/19/2006 5:09:18 PM
From: drbio45	Read Replies (1) of 90

They paid 17 million for a drug doing over 10 million. If they don't need a large sales force and it brings in positive cash flow because of that, I don't see it as a bad deal. If they can get a sales promotion kind of deal on MC-1 then it really makes sense So as I see it aggrastat has extremely little downside. Any increase in revenues is gravy MC-1 is a phase 3 drug with excellent efficacy and safety in a phase 2 trial which was so good the FDA allowed it to be recognized as a pivotal trial in a half billion dollar market, maybe more. No drug anywhere near them as competition in the indication. What is not to like?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next